Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an ant...

詳細記述

書誌詳細

主要な著者:	Maria Giovanna Lupo, Diletta Arcidiacono, Alice Zaramella, Fabio Fimiani, Paolo Calabrò, Angelo Baldassare Cefalù, Maurizio Averna, Laura D'Erasmo, Marcello Arca, Sara De Martin, Alberto Zambon, Nicola Ferri
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2021-09-01
シリーズ:	Atherosclerosis Plus
主題:	Lomitapide pcsk9 lp(a) Familial hypercholesterolemia
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2667089521000018
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!